Clinical Trials Logo

Clinical Trial Summary

Currently, data of the efficacy of trastuzumab plus pertuzumab and chemotherapy is limited in the HER2 positive metastatic breast cancer patients previously treated with trastuzumab during (neo)adjuvant and metastatic setting, and results are not consistent.The main purpose of this study is to evaluate the 6-month progression free survival(PFS) of trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy as first to third line therapy in Chinese patients with HER2 positive metastatic breast cancer who received trastuzumab previously.Primary Endpoint is 6-month Progression-free survival (PFS);Secondary Endpoint(s) include Progression-free survival (PFS) Overall Survival (OS);Objective Response Rate(ORR);

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05188495
Study type Observational
Source Beijing Cancer Hospital
Contact Ruyan Zhang
Phone +861088196380
Email [email protected]
Status Recruiting
Start date May 10, 2021
Completion date December 10, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05042791 - A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases Phase 2
Recruiting NCT04692831 - Testing a New Imaging Agent to Identify Cancer Phase 1
Recruiting NCT04385563 - A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC. Phase 3
Recruiting NCT04319757 - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Phase 1
Recruiting NCT03979339 - Feasibility of a New Technology for Isolating Circulating Tumour Cells N/A
Recruiting NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Active, not recruiting NCT03417544 - Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC Phase 2
Completed NCT02605915 - Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer Phase 1
Recruiting NCT05036252 - Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
Not yet recruiting NCT04778982 - Study of KN026 in Combination With Palbociclib With or Without Fulvestrant in Patients With Advanced HER2-positive Breast Cancer